VRSK Stock Analysis: Verisk Analytics | NASDAQ
Consulting Services | NASDAQ, USA | Market Cap: 25.309m USD | 12M Return: -27.3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 335M
EPS Trend: 98.5%
Qual. Beats: 2
Rev. Trend: 89.5%
Qual. Beats: 2
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Verisk Analytics, Inc. (NASDAQ: VRSK) is a data analytics and technology provider serving the global insurance industry, with operations spanning the United States and international markets. Its offerings are organized around two core areas: underwriting solutions (including policy language, rating rules, loss costs, catastrophe modelling, life insurance analytics, and specialty/reinsurance management) and claims solutions (covering property estimating, anti-fraud tools, casualty claims workflow, and international motor and personal injury claims).
The company sits within the GICS Industrials sector under the Research & Consulting Services sub-industry, and its business model is built on aggregating industry data and licensing analytics, software, and benchmarking tools to insurers, reinsurers, and related financial services firms. This subscription- and license-driven model creates recurring revenue tied to underwriting volume and claims activity across the property/casualty and life insurance markets.
Verisk was founded in 1971 and is headquartered in Jersey City, New Jersey. It completed its initial public offering in October 2009.
- Subscription underwriting solutions drive recurring revenue growth
- Catastrophe modeling demand rises with climate-driven disasters
- International markets accelerate revenue diversification
| Net Income: 910.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.25 > 0.02 and ΔFCF/TA 5.27 > 1.0 |
| NWC/Revenue: 0.68% < 20% (prev 12.76%; Δ -12.08% < -1%) |
| CFO/TA 0.30 > 3% & CFO 1.38b > Net Income 910.2m |
| Net Debt (4.27b) to EBITDA (1.67b): 2.56 < 3 |
| Current Ratio: 1.02 > 1.5 & < 3 |
| Outstanding Shares: last quarter (135.2m) vs 12m ago -4.06% < -2% |
| Gross Margin: 67.44% > 18% (prev 69.15%; Δ -1.71% > 0.5%) |
| Asset Turnover: 63.83% > 50% (prev 57.22%; Δ 6.61% > 0%) |
| Interest Coverage Ratio: 7.66 > 6 (EBIT TTM 1.36b / Interest Expense TTM 177.8m) |
| A: 0.00 (Total Current Assets 1.20b - Total Current Liabilities 1.18b) / Total Assets 4.60b |
| B: 1.74 (Retained Earnings 7.98b / Total Assets 4.60b) |
| C: 0.28 (EBIT TTM 1.36b / Avg Total Assets 4.86b) |
| D: -0.20 (Book Value of Equity -1.17b / Total Liabilities 5.77b) |
| Altman-Z'' = 7.36 = AAA |
| DSRI: 0.93 (Receivables 554.3m/564.4m, Revenue 3.10b/2.93b) |
| GMI: 1.03 (GM 69.15% / 67.44%) |
| AQI: 1.15 (AQ_t 0.58 / AQ_t-1 0.51) |
| SGI: 1.06 (Revenue 3.10b / 2.93b) |
| TATA: -0.10 (NI 910.2m - CFO 1.38b) / TA 4.60b) |
| Beneish M = -2.94 (Cap -4..+1) = A |
As of July 30, 2026, the stock is trading at USD 212.26 with a total of 3,127,373 shares traded. Over the past week, the price has changed by +8.71%, over one month by +18.44%, over three months by +20.48% and over the past year by -27.25%.
Current recommended Stop Loss: 203.20 (which is 4.3% or 1.3 ATR below the current price).
Verisk Analytics has received a consensus analysts rating of 3.39. Therefore, it is recommended to hold VRSK.
- StrongBuy: 3
- Buy: 3
- Hold: 10
- Sell: 2
- StrongSell: 0
| Analysts Target Price | 222.2 | 4.7% |
P/E Trailing = 29.3126
P/E Forward = 25.1889
P/S = 8.1583
P/B = 74.895
P/EG = 1.8259
Revenue TTM = 3.10b USD
EBIT TTM = 1.36b USD
EBITDA TTM = 1.67b USD
Long Term Debt = 4.20b USD (from longTermDebt, last quarter)
Short Term Debt = 283.3m USD (from shortTermDebt, last quarter)
Debt = 4.80b USD (from shortLongTermDebtTotal, last quarter) + Leases 170.7m
Net Debt = 4.27b USD (calculated: Debt 4.80b - CCE 525.2m)
Enterprise Value = 29.6b USD (25.3b + Debt 4.80b - CCE 525.2m)
Interest Coverage Ratio = 7.66 (Ebit TTM 1.36b / Interest Expense TTM 177.8m)
EV/FCF = 26.24x (Enterprise Value 29.6b / FCF TTM 1.13b)
FCF Yield = 3.81% (FCF TTM 1.13b / Enterprise Value 29.6b)
FCF Margin = 36.34% (FCF TTM 1.13b / Revenue TTM 3.10b)
Net Margin = 29.34% (Net Income TTM 910.2m / Revenue TTM 3.10b)
Gross Margin = 67.44% ((Revenue TTM 3.10b - Cost of Revenue TTM 1.01b) / Revenue TTM)
Gross Margin QoQ = 69.77% (prev 59.60%)
Tobins Q-Ratio = 6.43 (Enterprise Value 29.6b / Total Assets 4.60b)
Interest Expense / Debt = 3.71% (Interest Expense 177.8m / Debt 4.80b)
Taxrate = 23.09% (273.2m / 1.18b)
NOPAT = 1.05b (EBIT 1.36b * (1 - 23.09%))
Current Ratio = 1.02 (Total Current Assets 1.20b / Total Current Liabilities 1.18b)
Debt / Equity = -4.11 (negative equity) (Debt 4.80b / totalStockholderEquity, last quarter -1.17b)
Debt / EBITDA = 2.56 (Net Debt 4.27b / EBITDA 1.67b)
Debt / FCF = 3.79 (Net Debt 4.27b / FCF TTM 1.13b)
Total Stockholder Equity = -42.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 18.73% (Net Income 910.2m / Total Assets 4.60b)
RoE = -2.14k% (out of range, set to none) (Net Income TTM 910.2m / Total Stockholder Equity -42.6m)
RoCE = 32.70% (EBIT 1.36b / Capital Employed (Equity -42.6m + L.T.Debt 4.20b))
RoIC = 29.53% (NOPAT 1.05b / Invested Capital 3.55b)
WACC = 4.94% (E(25.3b)/V(30.1b) * Re(5.33%) + D(4.80b)/V(30.1b) * Rd(3.71%) * (1-Tc(0.23)))
Discount Rate = 5.33% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -95.66 | Cagr: -3.17%
[DCF] Terminal Value 77.87% ; FCFF base≈1.07b ; Y1≈1.22b ; Y5≈1.77b
[DCF] Fair Price = 171.2 (EV 26.7b - Net Debt 4.27b = Equity 22.4b / Shares 131.0m; r=8.35% [WACC [floored]]; 5y FCF grow 14.38% → 2.50% )
EPS Correlation: 98.52 | EPS CAGR: 10.05% | SUE: 1.21 | # QB: 2
Revenue Correlation: 89.52 | Revenue CAGR: 12.30% | SUE: 2.05 | # QB: 2
EPS current Quarter (2026-06-30): EPS=1.93 | Chg30d=-0.04% | Revisions=-21% | Analysts=16
EPS next Quarter (2026-09-30): EPS=1.95 | Chg30d=-0.17% | Revisions=-27% | Analysts=15
EPS current Year (2026-12-31): EPS=7.67 | Chg30d=+0.22% | Revisions=+25% | GrowthEPS=+7.1% | GrowthRev=+5.0%
EPS next Year (2027-12-31): EPS=8.67 | Chg30d=+0.16% | Revisions=+25% | GrowthEPS=+13.1% | GrowthRev=+6.8%
[Analyst] Revisions Ratio: -18% (up=10, down=15)